& Ravenscroft, J
The protein was eluted in G-buffer LCP (200 mM NaCl, 20 mM TrisHCl 7,5, 5% glycerol, 0.025% DDM, and 0.0025% CHS) containing 400 mM imidazole
Without confirmed systemic exposure data, it is impossible to distinguish between a genuinely inactive intervention and an inadequately delivered active compound a distinction of fundamental importance for both trial design and clinical application ( Several formulation strategies have been developed to address these pharmacokinetic limitations, each targeting a distinct barrier to absorption and systemic exposure
First improvement at 1 to 2 weeks, significant change by week 4
BHU takes on a what you see is what you get approach
The TB-500 component (thymosin -4) is a prohibited substance under WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times